Intellia Therapeutics (NTLA) Tops Q1 EPS by 26c

Intellia Therapeutics (NASDAQ: NTLA) reported Q1 EPS of ($1.12), $0.26 better than the analyst estimate of ($1.38). Revenue for the quarter came in at $28.94 million versus the consensus estimate of $10.65 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
• J.Jill (JILL) Tops Q2 EPS by 67c, Beats on Revenue; Offers Guidance
• Signet shares jump on Q2 profit beat, raised annual guidance